We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine.
-- Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series in Mid-2026, Followed by Topline Data from the Booster Dose...
-- VAX-31 Infant Indication: Investigational New Drug Application Cleared by FDA; Company Expects to Initiate VAX-31 Infant Phase 2 Study by the End of January 2025 -- -- VAX-31 Adult...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.56 | -0.638977635783 | 87.64 | 92.94 | 84.4637 | 1804217 | 87.18388711 | CS |
4 | -2.19 | -2.45323176879 | 89.27 | 94.76 | 84.4637 | 1148452 | 89.57420739 | CS |
12 | -25.61 | -22.7260626497 | 112.69 | 118.62 | 84.4637 | 1158518 | 96.79202437 | CS |
26 | 11.72 | 15.5520169851 | 75.36 | 121.055 | 70.45 | 1067535 | 96.36553657 | CS |
52 | 25.71 | 41.8934332736 | 61.37 | 121.055 | 53.83 | 914568 | 85.12224039 | CS |
156 | 63.48 | 268.983050847 | 23.6 | 121.055 | 16.78 | 735217 | 58.66059786 | CS |
260 | 63.52 | 269.60950764 | 23.56 | 121.055 | 15.51 | 568307 | 54.28424025 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions